IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers.
Antibody decay
COVID-19
IgG antibodies
SARS-CoV-2
mRNA vaccination
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
21
09
2021
revised:
27
10
2021
accepted:
27
10
2021
pubmed:
11
11
2021
medline:
15
12
2021
entrez:
10
11
2021
Statut:
ppublish
Résumé
Monitoring the immune response against SARS-CoV-2 is pivotal in the evaluation of long-term vaccine efficacy. Immunoglobulin G (IgG) antibodies represent an advisable tool to reach this goal, especially for the still poorly defined antibody trend induced by the new class of mRNA vaccines against SARS-CoV-2. Anti-Spike RBD IgG antibodies were monitored in a cohort of healthcare workers at CRO Aviano, National Cancer Institute, through MAGLUMI® chemiluminescence assay, at 1 and 4 months after full-schedule of BNT162b2 or mRNA-1273 vaccination. At 1 month after vaccination, 99.9% of 767 healthcare workers showed a reactive antibody response, which was inversely correlated with age, and positively associated with a previous history of COVID-19, and mRNA-1273 vaccination. Serological response was maintained in 99.6% of the 516 subjects monitored also at follow-up. An antibody decay from 559.8 AU/mL (IQR 359.7-845.7) to 92.7 AU/mL (IQR 65.1-148.6; p < 0.001) was observed, independently from age and sex. Our data supported the ability of SARS-CoV-2 mRNA vaccines to induce at least a 4 months-lasting IgG response, even outside the rules of clinical trials. The antibody decay observed at follow-up suggested to deepen the immune response characterization to identify subjects with low anti-SARS-CoV-2 immunity possibly requiring a vaccination boost.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Monitoring the immune response against SARS-CoV-2 is pivotal in the evaluation of long-term vaccine efficacy. Immunoglobulin G (IgG) antibodies represent an advisable tool to reach this goal, especially for the still poorly defined antibody trend induced by the new class of mRNA vaccines against SARS-CoV-2.
MATERIALS AND METHODS
METHODS
Anti-Spike RBD IgG antibodies were monitored in a cohort of healthcare workers at CRO Aviano, National Cancer Institute, through MAGLUMI® chemiluminescence assay, at 1 and 4 months after full-schedule of BNT162b2 or mRNA-1273 vaccination.
RESULTS
RESULTS
At 1 month after vaccination, 99.9% of 767 healthcare workers showed a reactive antibody response, which was inversely correlated with age, and positively associated with a previous history of COVID-19, and mRNA-1273 vaccination. Serological response was maintained in 99.6% of the 516 subjects monitored also at follow-up. An antibody decay from 559.8 AU/mL (IQR 359.7-845.7) to 92.7 AU/mL (IQR 65.1-148.6; p < 0.001) was observed, independently from age and sex.
CONCLUSION
CONCLUSIONS
Our data supported the ability of SARS-CoV-2 mRNA vaccines to induce at least a 4 months-lasting IgG response, even outside the rules of clinical trials. The antibody decay observed at follow-up suggested to deepen the immune response characterization to identify subjects with low anti-SARS-CoV-2 immunity possibly requiring a vaccination boost.
Identifiants
pubmed: 34755649
pii: S0009-8981(21)00379-X
doi: 10.1016/j.cca.2021.10.035
pmc: PMC8555109
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Immunoglobulin G
0
mRNA Vaccines
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-482Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Arthritis Rheumatol. 2020 Sep;72(9):1581-1582
pubmed: 32458534
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
J Infect. 2021 Sep;83(3):381-412
pubmed: 34161817
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
J Infect Dis. 2021 Oct 28;224(8):1294-1304
pubmed: 34089610
Nat Rev Immunol. 2021 Jun;21(6):395-404
pubmed: 33927374
BMC Med. 2021 Aug 23;19(1):208
pubmed: 34420521
Clin Chem Lab Med. 2020 Nov 19;59(2):e49-e51
pubmed: 33554502
PLoS Biol. 2018 Aug 10;16(8):e2006601
pubmed: 30096134
Cells. 2021 Jul 30;10(8):
pubmed: 34440710
Clin Chim Acta. 2021 Aug;519:60-63
pubmed: 33857476
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Clin Chem Lab Med. 2021 Apr 14;59(8):1444-1452
pubmed: 33855843
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Infect Public Health. 2021 Oct;14(10):1560-1562
pubmed: 34247945
Nat Commun. 2021 Jul 19;12(1):4383
pubmed: 34282139
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Diagnostics (Basel). 2021 May 25;11(6):
pubmed: 34070341
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Clin Transl Immunology. 2021 Jan 31;10(2):e1245
pubmed: 33552508
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
J Am Soc Nephrol. 2021 Sep;32(9):2147-2152
pubmed: 34112706
Arthritis Rheumatol. 2022 Jan;74(1):33-37
pubmed: 34196506
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
Ann Oncol. 2021 Aug;32(8):1051-1053
pubmed: 33932501
JAMA Netw Open. 2021 Sep 1;4(9):e2124331
pubmed: 34473262
J Infect. 2021 Aug;83(2):e4-e5
pubmed: 34214516
Int J Environ Res Public Health. 2021 Jun 14;18(12):
pubmed: 34198715
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Mult Scler. 2020 Sep;26(10):1261-1264
pubmed: 32762494